FA-based combinations to target the DNA damage response in glioblastoma

Ola  Rominiyi; Natividad Gomez-Roman; Yahia Al-Tamimi; David A Jellinek; Anthony Chalmers; Thomas A  Carroll; Spencer Collis

doi:10.1093/neuonc/noy130.066

FA-based combinations to target the DNA damage response in glioblastoma

Ola Rominiyi, Natividad Gomez-Roman, Yahia Al-Tamimi, David A Jellinek, Anthony Chalmers, Thomas A Carroll, Spencer Collis

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Conference abstract › peer-review

26 Downloads (Pure)

Abstract

Despite surgical resection followed by DNA-damaging adjuvant therapies, glioblastoma multiforme (GBM) remains incurable with a median survival of just 15.6 months. Anomalies within the DNA damage response (DDR) contribute to treatment resistance. We have previously shown that the Fanconi Anaemia (FA) pathway, a key DDR process, remains inactive in normal brain but is re-activated in GBM, making it an appealing foundational target for cancer-specific combination therapies. AIM: To determine whether combined targeting of the FA pathway and interconnected DDR processes could form a basis for new, effective multimodal therapies.

Original language	English
Pages (from-to)	v358
Number of pages	1
Journal	Neuro-Oncology
Volume	20
Issue number	S5
DOIs	https://doi.org/10.1093/neuonc/noy130.066
Publication status	Published - 1 Oct 2018

Keywords

glioblastoma
seizures
cancer
stem cells
cell survival
DNA
DNA damage
fanconi anemia
fluorescent antibody technique
glioma
RNA
neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/noy130.066

Rominiyi-etal-NO2018-FA-based-combinations-target-DNA-damage-response-glioblastomaFinal published version, 78.4 KBLicence: CC BY-NC 4.0

Cite this

@article{af4201e8342640efb89cbd98e5510432,

title = "FA-based combinations to target the DNA damage response in glioblastoma",

abstract = "Despite surgical resection followed by DNA-damaging adjuvant therapies, glioblastoma multiforme (GBM) remains incurable with a median survival of just 15.6 months. Anomalies within the DNA damage response (DDR) contribute to treatment resistance. We have previously shown that the Fanconi Anaemia (FA) pathway, a key DDR process, remains inactive in normal brain but is re-activated in GBM, making it an appealing foundational target for cancer-specific combination therapies. AIM: To determine whether combined targeting of the FA pathway and interconnected DDR processes could form a basis for new, effective multimodal therapies.",

keywords = "glioblastoma, seizures, cancer, stem cells, cell survival, DNA, DNA damage, fanconi anemia, fluorescent antibody technique, glioma, RNA, neoplasms",

author = "Ola Rominiyi and Natividad Gomez-Roman and Yahia Al-Tamimi and Jellinek, {David A} and Anthony Chalmers and Carroll, {Thomas A} and Spencer Collis",

note = "Copyright {\textcopyright} 2023 Society for Neuro-Oncology Mr Ola Rominiyi, Dr Natividad Gomez-Roman, Mr Yahia Al-Tamimi, Mr David A Jellinek, Prof Anthony J Chalmers, Mr Thomas A Carroll, Prof Beining Chen, Dr Spencer Collis, FA-based combinations to target the DNA damage response in glioblastoma, Neuro-Oncology, Volume 20, Issue suppl_5, October 2018, Page v358, https://doi.org/10.1093/neuonc/noy130.066 ",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/neuonc/noy130.066",

language = "English",

volume = "20",

pages = "v358",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "S5",

}

TY - JOUR

T1 - FA-based combinations to target the DNA damage response in glioblastoma

AU - Rominiyi, Ola

AU - Gomez-Roman, Natividad

AU - Al-Tamimi, Yahia

AU - Jellinek, David A

AU - Chalmers, Anthony

AU - Carroll, Thomas A

AU - Collis, Spencer

N1 - Copyright © 2023 Society for Neuro-Oncology Mr Ola Rominiyi, Dr Natividad Gomez-Roman, Mr Yahia Al-Tamimi, Mr David A Jellinek, Prof Anthony J Chalmers, Mr Thomas A Carroll, Prof Beining Chen, Dr Spencer Collis, FA-based combinations to target the DNA damage response in glioblastoma, Neuro-Oncology, Volume 20, Issue suppl_5, October 2018, Page v358, https://doi.org/10.1093/neuonc/noy130.066

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Despite surgical resection followed by DNA-damaging adjuvant therapies, glioblastoma multiforme (GBM) remains incurable with a median survival of just 15.6 months. Anomalies within the DNA damage response (DDR) contribute to treatment resistance. We have previously shown that the Fanconi Anaemia (FA) pathway, a key DDR process, remains inactive in normal brain but is re-activated in GBM, making it an appealing foundational target for cancer-specific combination therapies. AIM: To determine whether combined targeting of the FA pathway and interconnected DDR processes could form a basis for new, effective multimodal therapies.

AB - Despite surgical resection followed by DNA-damaging adjuvant therapies, glioblastoma multiforme (GBM) remains incurable with a median survival of just 15.6 months. Anomalies within the DNA damage response (DDR) contribute to treatment resistance. We have previously shown that the Fanconi Anaemia (FA) pathway, a key DDR process, remains inactive in normal brain but is re-activated in GBM, making it an appealing foundational target for cancer-specific combination therapies. AIM: To determine whether combined targeting of the FA pathway and interconnected DDR processes could form a basis for new, effective multimodal therapies.

KW - glioblastoma

KW - seizures

KW - cancer

KW - stem cells

KW - cell survival

KW - DNA

KW - DNA damage

KW - fanconi anemia

KW - fluorescent antibody technique

KW - glioma

KW - RNA

KW - neoplasms

U2 - 10.1093/neuonc/noy130.066

DO - 10.1093/neuonc/noy130.066

M3 - Conference abstract

SN - 1522-8517

VL - 20

SP - v358

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - S5

ER -

FA-based combinations to target the DNA damage response in glioblastoma

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this